FineMark National Bank & Trust’s Enanta Pharmaceuticals ENTA Stock Holding History

FineMark National Bank & Trust’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-582	Closed	-$13K	–	1338
2016 Q2	$13K	Sell	582 -391	-40%	-$10.2K	﹤0.01%	899
2016 Q1	$29K	Hold	973	–	–	﹤0.01%	707
2015 Q4	$32K	Hold	973	–	–	﹤0.01%	718
2015 Q3	$35K	Buy	973 +582	+149%	+$25K	﹤0.01%	719
2015 Q2	$18K	Hold	391	–	–	﹤0.01%	907
2015 Q1	$12K	Buy	+391	New	+$15.2K	﹤0.01%	960

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FineMark National Bank & Trust's ENTA Position: Q3 2016 in Review

FineMark National Bank & Trust sold out of Enanta Pharmaceuticals (ENTA) in Q3 2016, closing a stake of 582 shares — an estimated $13K sold.

FineMark National Bank & Trust first reported a position in ENTA in Q1 2015 and held it in 6 quarters. The position peaked at $35K in Q3 2015. 136 funds tracked by Wall St. Rank hold ENTA as of Q3 2016.

FineMark National Bank & Trust reported no remaining Enanta Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
FineMark National Bank & Trust sold 582 Enanta Pharmaceuticals shares in Q3 2016, an estimated $13K.
FineMark National Bank & Trust first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 6 quarters.
FineMark National Bank & Trust's Enanta Pharmaceuticals position peaked at $35K in Q3 2015.
136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2016.

Based on FineMark National Bank & Trust's 13F filing for Q3 2016, filed 10 Nov 2016.